Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

This study is testing a medication called Talazoparib to see how well it works for people with metastatic breast cancer. This drug is a targeted therapy designed to block proteins that cancer cells use to repair their own DNA, which may help stop the cancer from growing.

This study is for adults whose cancer has spread and who have a specific harmful BRCA mutation in their tumor that was not inherited from their parents. You must have tried other standard treatments like chemotherapy or hormone therapy first, and those treatments must have stopped working as intended.

If you join, you will be treated with Talazoparib and closely monitored by the research team to see how your body responds to the medicine. You will need to visit the study center for regular check-ups and follow-up tests to track your progress and manage any potential side effects.

This study is currently recruiting volunteers at medical centers in San Francisco, Atlanta, and Chicago. Because it is a phase 2 trial, the primary goal is to gather more information on how well the drug works for this specific group of patients.